BioSpace News Archive

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced final results from the interventional PATHFINDER study, which evaluated multi-cancer early detection screening using a blood test and the clinical care pathways following a “cancer signal detected” MCED test result in 6,662 individuals aged 50 years or older, an age group at elevated risk for cancer.

Merck announced KEYTRUDA, Merck’s anti-PD-1 therapy, plus chemotherapy continued to demonstrate a survival benefit and durable responses in two five-year exploratory analyses of pivotal Phase 3 studies as first-line treatment for metastatic non-small cell lung cancer.

Puma Biotechnology, Inc. announced the presentation of updated findings from the Phase II SUMMIT basket trial of neratinib for HER2 -mutant, metastatic cervical cancer at the 2022 European Society for Medical Oncology Congress, currently taking place in Paris, France.

BiomX Inc. announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.

Updated results after approximately four years of follow-up of the POSEIDON Phase III trial showed a limited course of tremelimumab when added to AstraZeneca’s IMFINZI® plus four cycles of chemotherapy demonstrated a sustained improvement in overall survival compared to chemotherapy alone in the 1st-line treatment of patients with Stage IV non-small cell lung cancer.

Detailed positive results from an interim analysis of the DESTINY-Lung02 Phase II trial showed ENHERTU® demonstrated clinically meaningful tumor responses in previously-treated patients with HER2-mutant unresectable and/or metastatic non-squamous non-small cell lung cancer.

Clovis Oncology, Inc., announced results from a subgroup analysis of data from the monotherapy comparison of the randomized, Phase 3 ATHENA trial.

GRAIL, LLC announced final results from the interventional PATHFINDER study, which evaluated multi-cancer early detection screening using a blood test and the clinical care pathways following a “cancer signal detected” MCED test result in 6,662 individuals aged 50 years or older, an age group at elevated risk for cancer.